142 related articles for article (PubMed ID: 31391026)
21. PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma.
Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Kallio P; Alitalo K; Seppänen H; Haglund C
BMC Cancer; 2016 Jul; 16():472. PubMed ID: 27411302
[TBL] [Abstract][Full Text] [Related]
22. Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenocarcinoma.
Nakagawa K; Akahori T; Nishiwada S; Nagai M; Nakamura K; Tanaka T; Tamamoto T; Ohbayashi C; Hasegawa M; Kichikawa K; Ikeda N; Sho M
Langenbecks Arch Surg; 2018 Sep; 403(6):693-700. PubMed ID: 30218193
[TBL] [Abstract][Full Text] [Related]
23. Preoperative neutrophil-to-lymphocyte ratio as a prognosticator in early stage pancreatic ductal adenocarcinoma.
Abe T; Amano H; Kobayashi T; Hanada K; Nakahara M; Ohdan H; Noriyuki T
Eur J Surg Oncol; 2018 Oct; 44(10):1573-1579. PubMed ID: 29807728
[TBL] [Abstract][Full Text] [Related]
24. Serum calcium level used as a prognostic predictor in patients with resectable pancreatic ductal adenocarcinoma.
Dong Q; Zhang Y; Yang XH; Jing W; Zheng LQ; Liu YP; Qu XJ; Li Z
Clin Res Hepatol Gastroenterol; 2014 Oct; 38(5):639-48. PubMed ID: 24630955
[TBL] [Abstract][Full Text] [Related]
25. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
26. Improved long-term outcomes after resection of pancreatic adenocarcinoma: a comparison between two time periods.
Serrano PE; Cleary SP; Dhani N; Kim PT; Greig PD; Leung K; Moulton CA; Gallinger S; Wei AC
Ann Surg Oncol; 2015 Apr; 22(4):1160-7. PubMed ID: 25348784
[TBL] [Abstract][Full Text] [Related]
27. Expression of estrogen receptor beta correlates with adverse prognosis in resected pancreatic adenocarcinoma.
Seeliger H; Pozios I; Assmann G; Zhao Y; Müller MH; Knösel T; Kreis ME; Bruns CJ
BMC Cancer; 2018 Oct; 18(1):1049. PubMed ID: 30373552
[TBL] [Abstract][Full Text] [Related]
28. Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival.
Ye HL; Li DD; Lin Q; Zhou Y; Zhou QB; Zeng B; Fu ZQ; Gao WC; Liu YM; Chen RW; Li ZH; Chen RF
World J Gastroenterol; 2015 Jun; 21(21):6621-30. PubMed ID: 26074700
[TBL] [Abstract][Full Text] [Related]
29. Additive value of pre-operative and one-month post-operative lymphocyte count for death-risk stratification in patients with resectable pancreatic cancer: a multicentric study.
d'Engremont C; Vernerey D; Pointet AL; Simone G; Fein F; Heyd B; Koch S; Vuitton L; Kim S; Jary M; Lamfichek N; Turco C; Lakkis Z; Berger A; Bonnetain F; Taieb J; Bachellier P; Borg C
BMC Cancer; 2016 Oct; 16(1):823. PubMed ID: 27782813
[TBL] [Abstract][Full Text] [Related]
30. High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis.
Neuzillet C; Couvelard A; Tijeras-Raballand A; de Mestier L; de Gramont A; Bédossa P; Paradis V; Sauvanet A; Bachet JB; Ruszniewski P; Raymond E; Hammel P; Cros J
Histopathology; 2015 Nov; 67(5):664-76. PubMed ID: 25809563
[TBL] [Abstract][Full Text] [Related]
31. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
[TBL] [Abstract][Full Text] [Related]
32. Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients.
Sun B; Liu X; Gao Y; Li L; Dong Z
Br J Biomed Sci; 2016 Oct; 73(4):152-157. PubMed ID: 27922430
[TBL] [Abstract][Full Text] [Related]
33. Validation of the pretreatment neutrophil-lymphocyte ratio as a predictor of overall survival in a cohort of patients with pancreatic ductal adenocarcinoma.
Ben Q; An W; Wang L; Wang W; Yu L; Yuan Y
Pancreas; 2015 Apr; 44(3):471-7. PubMed ID: 25423560
[TBL] [Abstract][Full Text] [Related]
34. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
[TBL] [Abstract][Full Text] [Related]
35. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
[TBL] [Abstract][Full Text] [Related]
36. Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma.
Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Fermér C; Nilsson O; Seppänen H; Haglund C
PLoS One; 2015; 10(6):e0129012. PubMed ID: 26053486
[TBL] [Abstract][Full Text] [Related]
37. Clinical and prognostic significance of serum transforming growth factor-beta1 levels in patients with pancreatic ductal adenocarcinoma.
Zhao J; Liang Y; Yin Q; Liu S; Wang Q; Tang Y; Cao C
Braz J Med Biol Res; 2016 Jul; 49(8):. PubMed ID: 27464025
[TBL] [Abstract][Full Text] [Related]
38. The Prognostic and Predictive Role of Epidermal Growth Factor Receptor in Surgical Resected Pancreatic Cancer.
Guo M; Luo G; Liu C; Cheng H; Lu Y; Jin K; Liu Z; Long J; Liu L; Xu J; Huang D; Ni Q; Yu X
Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27399694
[TBL] [Abstract][Full Text] [Related]
39. T-Helper 1 Immune Response in Metastatic Lymph Nodes of Pancreatic Ductal Adenocarcinoma: A Marker For Prolonged Survival.
Nizri E; Sternbach N; Bar-David S; Ben-Yehuda A; Gerstenhaber F; Ofir T; Wolf I; Weiner G; Lahat G; Klausner J
Ann Surg Oncol; 2018 Feb; 25(2):475-481. PubMed ID: 29124488
[TBL] [Abstract][Full Text] [Related]
40. Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study.
Bergquist JR; Puig CA; Shubert CR; Groeschl RT; Habermann EB; Kendrick ML; Nagorney DM; Smoot RL; Farnell MB; Truty MJ
J Am Coll Surg; 2016 Jul; 223(1):52-65. PubMed ID: 27049786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
